 VI. To assess the use of IUdR-DNA cellular incorporation measured by the investigational laboratory assays of flow cytometry and HPLC as an exploratory biomarker of IPdR for the following effects: the IUdR-DNA cellular incorporation in patients circulating granulocytes taken weekly during the 28-day IPdR MTD dose, on day 29, and week 8 as an exploratory biomarker of IPdR systemic toxicities to bone marrow as measured by complete blood count CBCdifferential values. 